FDA Alert: Rotarix Vaccine: Update to Clinicians and Public Health Professionals
Audience: Pediatric and ancestry rehearsal healthcare professionals, influential salubriousness professionals [UPDATED 05/16/2010] FDA has distinct it is appropriate for clinicians and robustness care professionals to resume the use of Rotarix and to endure the use of RotaTeq. Based on a careful ranking of laboratory results from the manufacturers and its own laboratories, a detailed review of the scientific literature, and input from controlled and public health experts, the operation is revising its recommendation to temporarily suspend use of the Rotarix vaccine. FDA has also unfaltering that RotaTeq vaccine should linger in use.
In its decision, FDA considered that both vaccines have numerically safety records, including clinical trials involving tens of thousands of patients as well as clinical meet with millions of recipients. FDA has no indication that either porcine circovirus (PCV1 or PCV2) poses a aegis imperil in humans, and notes that neither is known to cause infection or disorder in humans. The benefits of the vaccines are substantial, and embrace inhibiting of hospitalization for severe rotavirus sickness in the United States and of death in other parts of the world. he benefits overbalance the risk, which is theoretical.
FDA and the manufacturers will at to investigate the findings of PCV in rotavirus vaccines and will value advice from ongoing testing by FDA and the manufacturers. [Posted 03/22/2010] FDA is recommending that healthcare professionals in the interim interrupt the use of Rotarix, a vaccine second-hand to prevent rotavirus disease. FDA’s advice is a precaution taken while the agency learns more about the situation. FDA has educated that DNA from porcine circovirus group 1 (PCV1) is present in Rotarix.
PCV1 is not known to cause ailment in humans. There is no fact at this time that this finding poses a cover risk. Because available evidence supports the shelter of Rotarix, no medical follow-up is needed for patients who have been vaccinated with Rotarix. There are two licensed vaccines for rotavirus in the United States: RotaTeq and Rotarix. For children who have received one dosage of Rotarix, CDC advises that clinicians can superlative the series with RotaTeq for the next two doses.
Additional information, including data for healthcare professionals and parents, is provided in the certificate below.
Tags: healthcare, professionals, rotarix, rotateq, rotavirus, vaccine, vaccines